Physician profile
Claudia Dima
NPI 1407940307
$666.51
in general payments reported to CMS, 2019-2025
10 companies · $49.67 in 2025
The $49.67 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.91 · 2020: $40.48 · 2021: $51.53 · 2022: $78.99 · 2023: $371 · 2024: $43.85 · 2025: $49.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $227.75 | 2021-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.01 | 2019-2025 | Lifevest |
| Medtronic, INC. | $137.88 | 2023 | Resolute Onyx |
| Pfizer INC. | $25.85 | 2022-2023 | |
| Abbott Laboratories | $24.45 | 2025 | Perclose Prostyle |
| Amgen INC. | $22.55 | 2023 | Repatha |
| Chiesi USA, INC. | $21.04 | 2024 | Kengreal, Cleviprex |
| Digirad Health, INC | $12.14 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.48 | 2021 | |
| Travere Therapeutics, INC. | $2.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Dima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.